Young-Sil An
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Young-Sil An has a total of 277 co-authors. Here are the top co-authors by number of shared publications:
- Su Jin Lee
Department of Nuclear Medicine and Molecular Imaging, Ajou University School of Medicine, Suwon 16499, Republic of Korea
39 shared publications Joon-Kee Yoon
Department of Nuclear Medicine and Molecular Imaging
30 shared publications- Joon-Kee Yoon
Department of Nuclear Medicine and Molecular Imaging, Ajou University School of Medicine, Suwon 16499, Republic of Korea
13 shared publications - Yong Sik Jung
Department of Surgery, Ajou University School of Medicine, Suwon, South Korea
12 shared publications Seok-Ho Yoon
11 shared publications- Tae Hee Kim
Department of Radiology, Ajou University Medical Center, Suwon, Korea
9 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by MDPI AG in Tomography
- Vol. 12 (4) , 50
Clinical Potential of Artificial Bone Scintigraphy from Early-Phase Bone Scintigraphy Using Unpaired Image-to-Image Translation in Patients with Breast Cancer: A Single-Center Prospective Study
Objectives: The objective of this study is to investigate the clinical potential of generating artificial bone scintigraphy (aBS), defined here as a deep learning-generated bone scintigraphy image that simulates delayed-phase bone scintigraphy (dBS) characteristics, from early-phase bone scintigraphy (eBS) obtained with a short waiting time using an unpaired image-to-image translation method in patients with breast cancer (BC). Methods: In this single-center prospective study involving 245 patients with BC (195 for training and 50 for testing), eBS and dBS were performed. Using the contrastive unpaired translation (CUT) model, we trained with anterior and posterior images of the eBS and dBS from the training group. We then generated aBS images targeting dBS by inputting eBS from the test group for both anterior and posterior views. We conducted quantitative, qualitative, and visual assessments to evaluate aBS. Results: The points of the anterior and posterior images of aBS on the qualitative four-point and five-point rating scales were significantly higher than those of eBS (p < 0.0001). Three nuclear medicine physicians performed visual assessments, demonstrating consistent findings on the presence of bone metastases in both aBS and dBS. Their visual evaluations indicated that the bone-to-soft tissue contrast in aBS was superior to that in eBS. The quantitative metrics of aBS were superior to those of eBS. However, aBS was inferior to the targeted dBS in terms of qualitative and visual assessments. Conclusions: The aBS generated through CUT was superior to eBS in quantitative, qualitative, and visual assessments and preserved lesion-related information comparable to dBS. Although these findings do not support replacement of dBS for definitive diagnosis, they support the feasibility of aBS as an assistive delayed-phase-like image generation approach from earlier-acquired bone scintigraphy.
- 2 April 2026
- Published by MDPI AG in Tomography
- Vol. 12 (4) , 50
Open AccessClinical Potential of Artificial Bone Scintigraphy from Early-Phase Bone Scintigraphy Using Unpaired Image-to-Image Translation in Patients with Breast Cancer: A Single-Center Prospective Study
Objectives: The objective of this study is to investigate the clinical potential of generating artificial bone scintigraphy (aBS), defined here as a deep learning-generated bone scintigraphy image that simulates delayed-phase bone scintigraphy (dBS) characteristics, from early-phase bone scintigraphy (eBS) obtained with a short waiting time using an unpaired image-to-image translation method in patients with breast cancer (BC). Methods: In this single-center prospective study involving 245 patients with BC (195 for training and 50 for testing), eBS and dBS were performed. Using the contrastive unpaired translation (CUT) model, we trained with anterior and posterior images of the eBS and dBS from the training group. We then generated aBS images targeting dBS by inputting eBS from the test group for both anterior and posterior views. We conducted quantitative, qualitative, and visual assessments to evaluate aBS. Results: The points of the anterior and posterior images of aBS on the qualitative four-point and five-point rating scales were significantly higher than those of eBS (p < 0.0001). Three nuclear medicine physicians performed visual assessments, demonstrating consistent findings on the presence of bone metastases in both aBS and dBS. Their visual evaluations indicated that the bone-to-soft tissue contrast in aBS was superior to that in eBS. The quantitative metrics of aBS were superior to those of eBS. However, aBS was inferior to the targeted dBS in terms of qualitative and visual assessments. Conclusions: The aBS generated through CUT was superior to eBS in quantitative, qualitative, and visual assessments and preserved lesion-related information comparable to dBS. Although these findings do not support replacement of dBS for definitive diagnosis, they support the feasibility of aBS as an assistive delayed-phase-like image generation approach from earlier-acquired bone scintigraphy.
- Open Access
- 28 August 2025
- Published by Springer Nature in BMC Neuroscience
- Vol. 26 (1) , 1-8
Comparative study of 18F-labeled PET radiopharmaceuticals in an Alzheimer’s disease mouse model
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is the leading cause of dementia, characterized by memory loss, cognitive decline, and significant social and economic burdens. Despite extensive research into amyloid positron emission tomography (PET) radiopharmaceuticals, the effectiveness of various 18F-labeled tracers for imaging amyloid plaques in AD mouse models remains uncertain. This study aimed to evaluate the performance of three radiopharmaceuticals—18F-florbetaben (FBB), 18F-flutemetamol (FMM), and 18F-florapronol (FPN)—in differentiating amyloid deposition in AD and control mice. 18F-FMM and 18F-FBB demonstrated significantly higher standardized uptake value ratios (SUVRs) in AD mice than in controls. For 18F-FBB, the mean SUVR in AD mice was 1.06, significantly higher than the 0.81 in controls (p < 0.001). Similarly, 18F-FMM showed a mean SUVR of 0.97 in AD mice compared to 0.94 in controls (p = 0.024). In contrast, 18F-FPN did not show significant SUVR differences between AD and control groups (p = 0.071). Comparative analysis revealed that 18F-FBB exhibited a significantly greater SUVR difference between AD and control groups compared to 18F-FMM (p < 0.001). 18F-FBB emerged as the most effective radiopharmaceutical for imaging amyloid deposition in AD mouse models, providing superior differentiation between AD and control groups. These findings support the optimization of amyloid PET tracers for preclinical studies, facilitating advancements in Alzheimer’s research. Not applicable.
- 28 August 2025
- Published by Springer Nature in BMC Neuroscience
- Vol. 26 (1) , 1-8
Open AccessComparative study of 18F-labeled PET radiopharmaceuticals in an Alzheimer’s disease mouse model
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is the leading cause of dementia, characterized by memory loss, cognitive decline, and significant social and economic burdens. Despite extensive research into amyloid positron emission tomography (PET) radiopharmaceuticals, the effectiveness of various 18F-labeled tracers for imaging amyloid plaques in AD mouse models remains uncertain. This study aimed to evaluate the performance of three radiopharmaceuticals—18F-florbetaben (FBB), 18F-flutemetamol (FMM), and 18F-florapronol (FPN)—in differentiating amyloid deposition in AD and control mice. 18F-FMM and 18F-FBB demonstrated significantly higher standardized uptake value ratios (SUVRs) in AD mice than in controls. For 18F-FBB, the mean SUVR in AD mice was 1.06, significantly higher than the 0.81 in controls (p < 0.001). Similarly, 18F-FMM showed a mean SUVR of 0.97 in AD mice compared to 0.94 in controls (p = 0.024). In contrast, 18F-FPN did not show significant SUVR differences between AD and control groups (p = 0.071). Comparative analysis revealed that 18F-FBB exhibited a significantly greater SUVR difference between AD and control groups compared to 18F-FMM (p < 0.001). 18F-FBB emerged as the most effective radiopharmaceutical for imaging amyloid deposition in AD mouse models, providing superior differentiation between AD and control groups. These findings support the optimization of amyloid PET tracers for preclinical studies, facilitating advancements in Alzheimer’s research. Not applicable.
- 7 August 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (11) , e633-e637
The Role of Quantification Values in the Visual Interpretation of Dopamine Transporter PET Images
Background: This study aimed to identify the quantified uptake values that can aid the visual interpretation of dopamine transporter (DAT) PET images. Patients and Methods: A total of 155 patients (82 men, 73 women; mean age 67.7 y) who underwent [18F]-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane (18F-FP-CIT) PET scans for suspected Parkinson disease were included. Visual assessments classified 18F-FP-CIT uptake in the basal ganglia [caudate nucleus (CN) and putamen] as normal or abnormal, including the evaluation of asymmetry. The quantitative evaluation involved calculating the SUVR by dividing the basal ganglia SUV by the cerebellum SUV and determining the asymmetric index (AI). This study explored the relationship between these quantification values and visual interpretation, focusing on assessing asymmetric and normal uptake patterns. Results: Visual analysis indicated that 39.7% (123/310) of CN and 75.8% (235/310) of putamen exhibited abnormal 18F-FP-CIT uptake. Significant differences in the SUVR and AI values were observed between the visually normal and abnormal groups (P < 0.001 for both the CN and putamen). The SUVR demonstrated excellent diagnostic accuracy for visual normal uptake patterns in the putamen (AUC = 0.950, 93.2% sensitivity, and 89.3% specificity at a cutoff of 3.91) and CN (AUC = 0.932, 87.0% sensitivity, and 87.7% specificity at a cutoff of 2.73). The AI was also significant in evaluating visual asymmetry (AUC = 0.670, P = 0.004 for the CN; AUC = 0.855, P < 0.001 for the putamen). Conclusions: Our quantitative measures provide valuable support for the visual interpretation of 18F-FP-CIT PET images.
- 7 August 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (11) , e633-e637
The Role of Quantification Values in the Visual Interpretation of Dopamine Transporter PET Images
Background: This study aimed to identify the quantified uptake values that can aid the visual interpretation of dopamine transporter (DAT) PET images. Patients and Methods: A total of 155 patients (82 men, 73 women; mean age 67.7 y) who underwent [18F]-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane (18F-FP-CIT) PET scans for suspected Parkinson disease were included. Visual assessments classified 18F-FP-CIT uptake in the basal ganglia [caudate nucleus (CN) and putamen] as normal or abnormal, including the evaluation of asymmetry. The quantitative evaluation involved calculating the SUVR by dividing the basal ganglia SUV by the cerebellum SUV and determining the asymmetric index (AI). This study explored the relationship between these quantification values and visual interpretation, focusing on assessing asymmetric and normal uptake patterns. Results: Visual analysis indicated that 39.7% (123/310) of CN and 75.8% (235/310) of putamen exhibited abnormal 18F-FP-CIT uptake. Significant differences in the SUVR and AI values were observed between the visually normal and abnormal groups (P < 0.001 for both the CN and putamen). The SUVR demonstrated excellent diagnostic accuracy for visual normal uptake patterns in the putamen (AUC = 0.950, 93.2% sensitivity, and 89.3% specificity at a cutoff of 3.91) and CN (AUC = 0.932, 87.0% sensitivity, and 87.7% specificity at a cutoff of 2.73). The AI was also significant in evaluating visual asymmetry (AUC = 0.670, P = 0.004 for the CN; AUC = 0.855, P < 0.001 for the putamen). Conclusions: Our quantitative measures provide valuable support for the visual interpretation of 18F-FP-CIT PET images.
- 8 July 2025
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 27 (4) , 578-586
Combining Dopamine Transporter and Amyloid PET Tracer: A Preclinical Study on Dual-Target Imaging
Purpose This study aimed to evaluate the feasibility and diagnostic utility of a dual-target positron emission tomography (PET) imaging approach using a cocktail of N-3-[18F]fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane ([18F]FP-CIT) and [18F]florbetaben (FBB) for the simultaneous assessment of dopaminergic and amyloid changes in a preclinical setting. Procedures We utilized both Parkinson’s disease (PD) and Alzheimer’s disease (AD) mouse models, as well as a control group, to investigate the uptake of [18F]FP-CIT and [18F]FBB individually and in combination. PET imaging was conducted, and standardized uptake value ratios (SUVRs) were analyzed for each model across the striatal and cortical regions. Comparisons were made between single and cocktail PET scans to assess potential cross-interference of the tracers. Results In both PD and AD models, no statistically significant differences were observed in the SUVRs between single-tracer and cocktail PET scans in the striatum and cortex (p > 0.4 for striatal comparisons, p > 0.8 for cortical comparisons). Bland–Altman analysis showed no significant bias, supporting the interchangeability of SUVRs between single and cocktail PET scans. Conclusions This preclinical study suggests that [18F]FP-CIT and [18F]FBB PET imaging is a viable dual-target imaging approach for neurodegenerative disease evaluation. The method could streamline diagnostic workflows and improve patient convenience. Further clinical studies are warranted to validate the efficacy and safety of this approach in human populations.
- 8 July 2025
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 27 (4) , 578-586
Combining Dopamine Transporter and Amyloid PET Tracer: A Preclinical Study on Dual-Target Imaging
Purpose This study aimed to evaluate the feasibility and diagnostic utility of a dual-target positron emission tomography (PET) imaging approach using a cocktail of N-3-[18F]fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane ([18F]FP-CIT) and [18F]florbetaben (FBB) for the simultaneous assessment of dopaminergic and amyloid changes in a preclinical setting. Procedures We utilized both Parkinson’s disease (PD) and Alzheimer’s disease (AD) mouse models, as well as a control group, to investigate the uptake of [18F]FP-CIT and [18F]FBB individually and in combination. PET imaging was conducted, and standardized uptake value ratios (SUVRs) were analyzed for each model across the striatal and cortical regions. Comparisons were made between single and cocktail PET scans to assess potential cross-interference of the tracers. Results In both PD and AD models, no statistically significant differences were observed in the SUVRs between single-tracer and cocktail PET scans in the striatum and cortex (p > 0.4 for striatal comparisons, p > 0.8 for cortical comparisons). Bland–Altman analysis showed no significant bias, supporting the interchangeability of SUVRs between single and cocktail PET scans. Conclusions This preclinical study suggests that [18F]FP-CIT and [18F]FBB PET imaging is a viable dual-target imaging approach for neurodegenerative disease evaluation. The method could streamline diagnostic workflows and improve patient convenience. Further clinical studies are warranted to validate the efficacy and safety of this approach in human populations.
- Open Access
- 25 June 2025
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 22 (6) , 699-713
Transcriptional Landscape and Biomarker Discovery for Endoplasmic Reticulum Stress in Alzheimer’s Disease: An Ex Vivo Study Using Patients-Derived Dermal Fibroblasts
Objective Numerous studies have identified various risk factors associated with Alzheimer’s disease (AD). However, the experimental limitations of disease modeling make it challenging to directly interpret their effects. These limitations include constraints of postmortem samples, animal experiments, and challenges associated with brain tissue studies. Ex vivo experiments effectively address these issues by enabling patient-specific identification and highlighting potential biomarkers. This study aimed to characterize the transcriptional profile of fibroblasts derived from patients with AD in response to endoplasmic reticulum (ER) stress and propose potential biomarkers.Methods We utilized an ex vivo platform to identify genes differentially responsive to ER stress. The transcriptional feature of fibroblasts in both healthy controls (n=22) and patients with AD (n=20) was analyzed using bulk RNA sequencing. The cytotoxicity of the selected target gene was evaluated through knockdown experiments.Results A total of 468 differentially expressed genes (DEGs) were identified. Gene ontology and pathway enrichment analysis revealed that 210 DEGs, which were less responsive in AD, are involved in lipid-related terms and pathways. By narrowing down AD-related genes, we identified 49 highly reliable AD-associated genes. The most significant gene, DCTN2, exhibited a fold change that positively correlated with cognitive function and negatively correlated with blood-based biomarkers (pTau217, amyloid beta 42/40 ratio), aligning with the amyloid/Tau/neurodegeneration research criteria for AD. Additionally, the knockdown of DCTN2 in glial cell lines resulted in increased cell toxicity and apoptosis.Conclusion Identifying differentially responsive genes in ex vivo experiments not only provides insights into the pathology of AD but also offers potential biomarkers for disease diagnosis.
- 25 June 2025
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 22 (6) , 699-713
Open AccessTranscriptional Landscape and Biomarker Discovery for Endoplasmic Reticulum Stress in Alzheimer’s Disease: An Ex Vivo Study Using Patients-Derived Dermal Fibroblasts
Objective Numerous studies have identified various risk factors associated with Alzheimer’s disease (AD). However, the experimental limitations of disease modeling make it challenging to directly interpret their effects. These limitations include constraints of postmortem samples, animal experiments, and challenges associated with brain tissue studies. Ex vivo experiments effectively address these issues by enabling patient-specific identification and highlighting potential biomarkers. This study aimed to characterize the transcriptional profile of fibroblasts derived from patients with AD in response to endoplasmic reticulum (ER) stress and propose potential biomarkers.Methods We utilized an ex vivo platform to identify genes differentially responsive to ER stress. The transcriptional feature of fibroblasts in both healthy controls (n=22) and patients with AD (n=20) was analyzed using bulk RNA sequencing. The cytotoxicity of the selected target gene was evaluated through knockdown experiments.Results A total of 468 differentially expressed genes (DEGs) were identified. Gene ontology and pathway enrichment analysis revealed that 210 DEGs, which were less responsive in AD, are involved in lipid-related terms and pathways. By narrowing down AD-related genes, we identified 49 highly reliable AD-associated genes. The most significant gene, DCTN2, exhibited a fold change that positively correlated with cognitive function and negatively correlated with blood-based biomarkers (pTau217, amyloid beta 42/40 ratio), aligning with the amyloid/Tau/neurodegeneration research criteria for AD. Additionally, the knockdown of DCTN2 in glial cell lines resulted in increased cell toxicity and apoptosis.Conclusion Identifying differentially responsive genes in ex vivo experiments not only provides insights into the pathology of AD but also offers potential biomarkers for disease diagnosis.
- 23 June 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 106 (3) , 1198-1211
Machine learning-based prediction of amyloid positivity using early-phase F-18 flutemetamol PET
Background: Previous studies have suggested that early-phase imaging of amyloid positron emission tomography (PET) may offer information for predicting amyloid positivity. Objective: This study aimed to evaluate whether early-phase fluorine-18 flutemetamol (eFMM) PET images provide valuable information for predicting amyloid positivity using machine learning (ML) models and whether incorporating clinical and neuropsychological features improves predictive performance. Methods: In total, 454 patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) were enrolled and randomly divided into training (n = 354) and test (n = 100) groups. We developed ML models using logistic regression (LR) and linear discriminant analyses (LDA) for predicting amyloid positivity: eFMM features alone (eFMM model), eFMM features combined with clinical features (eFMM + C model), eFMM features combined with neuropsychological features (eFMM + N model), eFMM features combined with both clinical and neuropsychological features (eFMM + C + N model), clinical and neuropsychological features combined (C + N model), and dFMM features alone (dFMM model). Results: In the test group, the eFMM models achieved areas under the receiver operating characteristic curves (AUROCs) of 0.791 (LR) and 0.779 (LDA). The eFMM + C + N models significantly improved predictive performance, with AUROCs of 0.902 for both LR and LDA, outperforming the eFMM models. Conclusions: ML predictive models using eFMM PET data demonstrated fair performance in predicting amyloid positivity in patients with MCI and AD. The addition of relevant clinical and neuropsychological features further enhanced the predictive performance of the eFMM models, achieving excellent performance.
- 23 June 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 106 (3) , 1198-1211
Machine learning-based prediction of amyloid positivity using early-phase F-18 flutemetamol PET
Background: Previous studies have suggested that early-phase imaging of amyloid positron emission tomography (PET) may offer information for predicting amyloid positivity. Objective: This study aimed to evaluate whether early-phase fluorine-18 flutemetamol (eFMM) PET images provide valuable information for predicting amyloid positivity using machine learning (ML) models and whether incorporating clinical and neuropsychological features improves predictive performance. Methods: In total, 454 patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) were enrolled and randomly divided into training (n = 354) and test (n = 100) groups. We developed ML models using logistic regression (LR) and linear discriminant analyses (LDA) for predicting amyloid positivity: eFMM features alone (eFMM model), eFMM features combined with clinical features (eFMM + C model), eFMM features combined with neuropsychological features (eFMM + N model), eFMM features combined with both clinical and neuropsychological features (eFMM + C + N model), clinical and neuropsychological features combined (C + N model), and dFMM features alone (dFMM model). Results: In the test group, the eFMM models achieved areas under the receiver operating characteristic curves (AUROCs) of 0.791 (LR) and 0.779 (LDA). The eFMM + C + N models significantly improved predictive performance, with AUROCs of 0.902 for both LR and LDA, outperforming the eFMM models. Conclusions: ML predictive models using eFMM PET data demonstrated fair performance in predicting amyloid positivity in patients with MCI and AD. The addition of relevant clinical and neuropsychological features further enhanced the predictive performance of the eFMM models, achieving excellent performance.
- 6 March 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (8) , 800-801
Incidental Detection of Meningioma on 18F-Flutemetamol PET
Meningioma is typically a benign tumor that may incidentally be found on imaging. This case demonstrates the utility of 18F-flutemetamol (FMM) PET/CT in an 80-year-old woman evaluated for memory decline. Although the scan was performed for dementia assessment, it revealed an incidental mass in the frontal region. Early-phase PET showed relatively low uptake, while delayed-phase imaging displayed intense uptake of 18F-FMM. Magnetic resonance imaging and surgical pathology confirmed the lesion as a meningioma. This report may aid in interpreting incidental mass lesions on 18F-FMM PET, providing a reference for physicians who may encounter similar findings.
- 6 March 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (8) , 800-801
Incidental Detection of Meningioma on 18F-Flutemetamol PET
Meningioma is typically a benign tumor that may incidentally be found on imaging. This case demonstrates the utility of 18F-flutemetamol (FMM) PET/CT in an 80-year-old woman evaluated for memory decline. Although the scan was performed for dementia assessment, it revealed an incidental mass in the frontal region. Early-phase PET showed relatively low uptake, while delayed-phase imaging displayed intense uptake of 18F-FMM. Magnetic resonance imaging and surgical pathology confirmed the lesion as a meningioma. This report may aid in interpreting incidental mass lesions on 18F-FMM PET, providing a reference for physicians who may encounter similar findings.
- 16 February 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 104 (1) , 232-244
Comparative analysis of Elecsys and ELISA for differentiating amyloid-PET status in a Korean memory clinic based on cerebrospinal fluid biomarkers
Background: The adoption of Alzheimer's disease (AD) biomarkers in clinical practice is expected to increase following recent approval of disease-modifying therapies. Fully automated immunoassays, Elecsys platform, offer convenience and enhanced reliability. Objective: This study was performed to evaluate the performance of the Elecsys assay in a Korean clinical setting, comparing its effectiveness to ELISA for detecting amyloid-PET positivity. Methods: Cerebrospinal fluid (CSF) Aβ 42 , pTau 181 , tTau, pTau 181 /Aβ 42 , and tTau/Aβ 42 were evaluated using Elecsys kits on a Cobas e 411 analyzer and manual Innotest ELISA with paired frozen samples ( n = 118) from subjects with cognitive status ranging from unimpaired to mild cognitive impairment and dementia. Results: Strong linear correlations were observed between Elecsys- and ELISA-measured Aβ 42 , pTau 181 , and tTau levels. Receiver operating characteristic-based cutoff points for pTau 181 /Aβ 42 (0.0252) and tTau/Aβ 42 (0.258) in Elecsys demonstrated the highest areas under the curve (0.97 and 0.96) and predictive values (96.6% for both) for detecting amyloid-PET abnormalities. No cases of abnormal amyloid PET status were found without concurrent abnormal CSF biomarkers when considering Elecsys Aβ 42 and the pTau 181 /Aβ 42 ratio simultaneously. In addition, previously established cutoffs for combined ratios effectively differentiated amyloid PET status in our samples. Conclusions: This study demonstrated the utility of Elecsys-measured CSF AD biomarkers in agreement with amyloid-PET classification in the Korean population. The pTau 181 /Aβ 42 and tTau/Aβ 42 ratios were the most accurate in detecting amyloid-PET (+), with Elecsys showing higher accuracy than ELISA. The study also supported the applicability of common cutoffs from Western countries for these biomarkers in our samples.
- 16 February 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 104 (1) , 232-244
Comparative analysis of Elecsys and ELISA for differentiating amyloid-PET status in a Korean memory clinic based on cerebrospinal fluid biomarkers
Background: The adoption of Alzheimer's disease (AD) biomarkers in clinical practice is expected to increase following recent approval of disease-modifying therapies. Fully automated immunoassays, Elecsys platform, offer convenience and enhanced reliability. Objective: This study was performed to evaluate the performance of the Elecsys assay in a Korean clinical setting, comparing its effectiveness to ELISA for detecting amyloid-PET positivity. Methods: Cerebrospinal fluid (CSF) Aβ 42 , pTau 181 , tTau, pTau 181 /Aβ 42 , and tTau/Aβ 42 were evaluated using Elecsys kits on a Cobas e 411 analyzer and manual Innotest ELISA with paired frozen samples ( n = 118) from subjects with cognitive status ranging from unimpaired to mild cognitive impairment and dementia. Results: Strong linear correlations were observed between Elecsys- and ELISA-measured Aβ 42 , pTau 181 , and tTau levels. Receiver operating characteristic-based cutoff points for pTau 181 /Aβ 42 (0.0252) and tTau/Aβ 42 (0.258) in Elecsys demonstrated the highest areas under the curve (0.97 and 0.96) and predictive values (96.6% for both) for detecting amyloid-PET abnormalities. No cases of abnormal amyloid PET status were found without concurrent abnormal CSF biomarkers when considering Elecsys Aβ 42 and the pTau 181 /Aβ 42 ratio simultaneously. In addition, previously established cutoffs for combined ratios effectively differentiated amyloid PET status in our samples. Conclusions: This study demonstrated the utility of Elecsys-measured CSF AD biomarkers in agreement with amyloid-PET classification in the Korean population. The pTau 181 /Aβ 42 and tTau/Aβ 42 ratios were the most accurate in detecting amyloid-PET (+), with Elecsys showing higher accuracy than ELISA. The study also supported the applicability of common cutoffs from Western countries for these biomarkers in our samples.
- Open Access
- 8 January 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 15 (1) , 1-7
Establishing cutoff values for visual amyloid positivity in [18F]flutemetamol PET
This study aimed to establish the optimal cutoff values for visual amyloid positivity using standardized uptake value ratios (SUVRs) in [18F]flutemetamol (FMM) positron emission tomography (PET) imaging. Given the variability in amyloid assessment, our goal was to determine cutoff values that enhance diagnostic accuracy and assist clinicians in reliably identifying amyloid positivity. The identified cutoff values for visual amyloid positivity were > 1.6 for the cerebellar gray matter, > 1.38 for the whole cerebellum, and > 0.63 for the pons, yielding high sensitivity (95.5%, 94.5%, and 95.8%, respectively) and specificity (91.2%, 94.3%, and 95.2%, respectively). The SUVR cutoff values demonstrated excellent diagnostic performance, supporting their clinical use in assessing visual amyloid positivity in [18F]FMM PET imaging.
- 8 January 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 15 (1) , 1-7
Open AccessEstablishing cutoff values for visual amyloid positivity in [18F]flutemetamol PET
This study aimed to establish the optimal cutoff values for visual amyloid positivity using standardized uptake value ratios (SUVRs) in [18F]flutemetamol (FMM) positron emission tomography (PET) imaging. Given the variability in amyloid assessment, our goal was to determine cutoff values that enhance diagnostic accuracy and assist clinicians in reliably identifying amyloid positivity. The identified cutoff values for visual amyloid positivity were > 1.6 for the cerebellar gray matter, > 1.38 for the whole cerebellum, and > 0.63 for the pons, yielding high sensitivity (95.5%, 94.5%, and 95.8%, respectively) and specificity (91.2%, 94.3%, and 95.2%, respectively). The SUVR cutoff values demonstrated excellent diagnostic performance, supporting their clinical use in assessing visual amyloid positivity in [18F]FMM PET imaging.
- Open Access
- 23 December 2024
- Published by MDPI AG in Tomography
- Vol. 10 (12) , 2144-2157
Automated Measurement of Effective Radiation Dose by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Background/Objectives: Calculating the radiation dose from CT in 18F-PET/CT examinations poses a significant challenge. The objective of this study is to develop a deep learning-based automated program that standardizes the measurement of radiation doses. Methods: The torso CT was segmented into six distinct regions using TotalSegmentator. An automated program was employed to extract the necessary information and calculate the effective dose (ED) of PET/CT. The accuracy of our automated program was verified by comparing the EDs calculated by the program with those determined by a nuclear medicine physician (n = 30). Additionally, we compared the EDs obtained from an older PET/CT scanner with those from a newer PET/CT scanner (n = 42). Results: The CT ED calculated by the automated program was not significantly different from that calculated by the nuclear medicine physician (3.67 ± 0.61 mSv and 3.62 ± 0.60 mSv, respectively, p = 0.7623). Similarly, the total ED showed no significant difference between the two calculation methods (8.10 ± 1.40 mSv and 8.05 ± 1.39 mSv, respectively, p = 0.8957). A very strong correlation was observed in both the CT ED and total ED between the two measurements (r2 = 0.9981 and 0.9996, respectively). The automated program showed excellent repeatability and reproducibility. When comparing the older and newer PET/CT scanners, the PET ED was significantly lower in the newer scanner than in the older scanner (4.39 ± 0.91 mSv and 6.00 ± 1.17 mSv, respectively, p < 0.0001). Consequently, the total ED was significantly lower in the newer scanner than in the older scanner (8.22 ± 1.53 mSv and 9.65 ± 1.34 mSv, respectively, p < 0.0001). Conclusions: We successfully developed an automated program for calculating the ED of torso 18F-PET/CT. By integrating a deep learning model, the program effectively eliminated inter-operator variability.
- 23 December 2024
- Published by MDPI AG in Tomography
- Vol. 10 (12) , 2144-2157
Open AccessAutomated Measurement of Effective Radiation Dose by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Background/Objectives: Calculating the radiation dose from CT in 18F-PET/CT examinations poses a significant challenge. The objective of this study is to develop a deep learning-based automated program that standardizes the measurement of radiation doses. Methods: The torso CT was segmented into six distinct regions using TotalSegmentator. An automated program was employed to extract the necessary information and calculate the effective dose (ED) of PET/CT. The accuracy of our automated program was verified by comparing the EDs calculated by the program with those determined by a nuclear medicine physician (n = 30). Additionally, we compared the EDs obtained from an older PET/CT scanner with those from a newer PET/CT scanner (n = 42). Results: The CT ED calculated by the automated program was not significantly different from that calculated by the nuclear medicine physician (3.67 ± 0.61 mSv and 3.62 ± 0.60 mSv, respectively, p = 0.7623). Similarly, the total ED showed no significant difference between the two calculation methods (8.10 ± 1.40 mSv and 8.05 ± 1.39 mSv, respectively, p = 0.8957). A very strong correlation was observed in both the CT ED and total ED between the two measurements (r2 = 0.9981 and 0.9996, respectively). The automated program showed excellent repeatability and reproducibility. When comparing the older and newer PET/CT scanners, the PET ED was significantly lower in the newer scanner than in the older scanner (4.39 ± 0.91 mSv and 6.00 ± 1.17 mSv, respectively, p < 0.0001). Consequently, the total ED was significantly lower in the newer scanner than in the older scanner (8.22 ± 1.53 mSv and 9.65 ± 1.34 mSv, respectively, p < 0.0001). Conclusions: We successfully developed an automated program for calculating the ED of torso 18F-PET/CT. By integrating a deep learning model, the program effectively eliminated inter-operator variability.